Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Mar 29, 2017
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients
Designated One of the 'Best Posters' by EAU, Results Highlight Expanded Value of Genomic Prostate Score™ in Assessing Risk and Long-term Outcomes in Patients Across Stages of Disease
Mar 24, 2017
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence Score® Results
Mar 20, 2017
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy Decisions in Node-negative and Node-positive Disease and Support Growing Adoption of Test
Feb 28, 2017
Genomic Health to Present at the Cowen and Company 37th Annual Health Care Conference
REDWOOD CITY, Calif. , Feb. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the Cowen and Company 37 th Annual Health Care Conference at the Marriot Copley Place in Boston
Feb 16, 2017
Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection
Presentations at 2017 ASCO Genitourinary Cancers Symposium in Orlando, Feb. 16-18, Underscore Test's Clinical Utility in Low- and Intermediate-risk Patients
Feb 14, 2017
Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
Achieved Profit in the Fourth Quarter of 2016; Guides to Full Year Profit in 2017
Delivered 14 Percent Revenue Growth and 11 Percent Test Growth in 2016
Generated $3.6M Prostate Revenue and Increased Prostate Test Volume by 29 Percent in the Fourth Quarter
Conference Call Today at 4:30 p.m. ET
Feb 07, 2017
Genomic Health to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 14, 2017
REDWOOD CITY, Calif. , Feb. 7, 2017 /PRNewswire/ --  Genomic Health, Inc.  (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 14 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2016 financial results.  The call and
Jan 03, 2017
Genomic Health to Present at the 35th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Jan. 3, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 35 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Dec 22, 2016
Genomic Health Announces Inclusion of Oncotype DX® in the 8th Edition of American Joint Committee on Cancer (AJCC) Criteria for Breast Cancer Staging
For the First Time, AJCC Adds Molecular Markers to Staging Criteria, Including Oncotype DX along with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 Status
Dec 09, 2016
Genomic Health Announces Results from Multiple Oncotype DX® Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World
Presentations at 2016 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) Highlight Unique Value of Oncotype DX in Tailoring Treatment Across the Breast Cancer Patient Journey